The Boston biotech builds human tissue models on microfluidic chips, then studies their responses with imaging and AI. Its wager: better drug predictions begin with better experiments.
Drug development still asks mice to predict people. Viscient’s nine-person team is building human liver disease in a dish - then using it to decide which medicines deserve a clinical trial.